Loading…
Employees: 1,738
Size Hainan Haiyao (000566.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $710M, the 3034th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.06 on 6 Nov 2026.
Performance Over six months the shares fell 18.8%, against -5.6% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 18.0% over the last twelve months (peer median +16.1%); the operating margin is -50.0% (peer median 15.1%).
Valuation It trades at 11.2× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 17).
Capital Return on invested capital runs 10.5 points below its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥673M | CN¥825M | CN¥971M | CN¥1.46B | CN¥1.76B |
| Revenue growth | — | -15% | -33% | -17% | — |
| Gross profit | CN¥239M | CN¥129M | CN¥265M | CN¥519M | CN¥706M |
| EBITDA | n/a | -CN¥47.2M | -CN¥460M | CN¥163M | CN¥29.2M |
| Net income | -CN¥533M | -CN¥430M | -CN¥1.53B | -CN¥106M | CN¥10.5M |
| Free cash flow | -CN¥115M | -CN¥50.9M | -CN¥184M | -CN¥73.5M | -CN¥113M |
| Capital expenditure | CN¥154M | CN¥143M | CN¥176M | CN¥211M | CN¥264M |
| Total debt | CN¥3.21B | CN¥4.82B | CN¥4.56B | CN¥4.24B | CN¥4.04B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000566.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -5.9% | 9th lowest of 21 |
| 6-month return | -18.8% | -5.6% | 7th lowest of 21 |
| Distance from 52-week high | -56.1% | -26.6% | 3rd lowest of 21 |
| Revenue growth (TTM) | -18.0% | +16.1% | 3rd lowest of 17 |
| Operating margin | -50.0% | 15.1% | lowest of 16 |
| EV / Sales | 11.2× | 3.0× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -10.5 pp | +1.3 pp | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | 11.2× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | 1.7× | -7.5% | -2.8% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 27.3× | 10.5% | -25.1% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 8.7× | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | 6.6× | 37.0% | +10.1% |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 1.5× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | 3.5× | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 2.7× | n/a | n/a |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 0.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 3.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | 6.2× | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 2.5× | -1.1% | +22.1% |